JP2022514385A5 - - Google Patents

Info

Publication number
JP2022514385A5
JP2022514385A5 JP2021535679A JP2021535679A JP2022514385A5 JP 2022514385 A5 JP2022514385 A5 JP 2022514385A5 JP 2021535679 A JP2021535679 A JP 2021535679A JP 2021535679 A JP2021535679 A JP 2021535679A JP 2022514385 A5 JP2022514385 A5 JP 2022514385A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
hydrogen
independently
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021535679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514385A (ja
JP7692830B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/067953 external-priority patent/WO2020132504A1/en
Publication of JP2022514385A publication Critical patent/JP2022514385A/ja
Publication of JP2022514385A5 publication Critical patent/JP2022514385A5/ja
Priority to JP2024094279A priority Critical patent/JP7858720B2/ja
Application granted granted Critical
Publication of JP7692830B2 publication Critical patent/JP7692830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021535679A 2018-12-21 2019-12-20 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物 Active JP7692830B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024094279A JP7858720B2 (ja) 2018-12-21 2024-06-11 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862784229P 2018-12-21 2018-12-21
US201862784222P 2018-12-21 2018-12-21
US62/784,229 2018-12-21
US62/784,222 2018-12-21
PCT/US2019/067953 WO2020132504A1 (en) 2018-12-21 2019-12-20 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024094279A Division JP7858720B2 (ja) 2018-12-21 2024-06-11 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物

Publications (3)

Publication Number Publication Date
JP2022514385A JP2022514385A (ja) 2022-02-10
JP2022514385A5 true JP2022514385A5 (cg-RX-API-DMAC7.html) 2022-11-18
JP7692830B2 JP7692830B2 (ja) 2025-06-16

Family

ID=69591712

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535679A Active JP7692830B2 (ja) 2018-12-21 2019-12-20 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物
JP2024094279A Active JP7858720B2 (ja) 2018-12-21 2024-06-11 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024094279A Active JP7858720B2 (ja) 2018-12-21 2024-06-11 3α-ヒドロキシ-17β-アミド神経刺激性ステロイドおよびその組成物

Country Status (12)

Country Link
US (1) US20220372067A1 (cg-RX-API-DMAC7.html)
EP (1) EP3898646B1 (cg-RX-API-DMAC7.html)
JP (2) JP7692830B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210107050A (cg-RX-API-DMAC7.html)
CN (1) CN113195512A (cg-RX-API-DMAC7.html)
AU (2) AU2019403415B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021012242A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124371A1 (cg-RX-API-DMAC7.html)
IL (1) IL284183A (cg-RX-API-DMAC7.html)
MX (2) MX2021007504A (cg-RX-API-DMAC7.html)
TW (2) TWI848034B (cg-RX-API-DMAC7.html)
WO (1) WO2020132504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
IL312610B2 (en) 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物
CN115768781A (zh) * 2020-06-24 2023-03-07 萨奇治疗股份有限公司 3.α.-羟基,17.β.-C(O)-N-芳基取代的神经活性类固醇及其组合物
CN119192275B (zh) * 2024-08-22 2025-05-30 湖南玉新药业有限公司 一种3-羰基-4-氮杂-5α-雄甾-17β-羧酸化合物的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US9512170B2 (en) * 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
MY190408A (en) * 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
DK3258939T3 (da) * 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
IL312610B2 (en) * 2018-12-05 2026-05-01 Sage Therapeutics Llc Neuroactive steroids and methods of using them
TWI848034B (zh) * 2018-12-21 2024-07-11 美商賽吉醫療公司 神經活性類固醇及其組合物

Similar Documents

Publication Publication Date Title
JP2022510683A5 (cg-RX-API-DMAC7.html)
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
JP2021527126A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
BR112020008825A2 (pt) moduladores da via de estresse integrada
JP2022504607A5 (cg-RX-API-DMAC7.html)
JP2017531619A5 (cg-RX-API-DMAC7.html)
JP2020517707A5 (cg-RX-API-DMAC7.html)
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
JP2019520417A5 (cg-RX-API-DMAC7.html)
RU2020131091A (ru) Композиции и способы для лечения расстройств цнс
JP2021510695A5 (cg-RX-API-DMAC7.html)
BR112020008833A2 (pt) moduladores da via de estresse integrada
JP2019500387A5 (cg-RX-API-DMAC7.html)
JP2023520925A5 (cg-RX-API-DMAC7.html)
JP2016512531A5 (cg-RX-API-DMAC7.html)
JP2019505541A5 (cg-RX-API-DMAC7.html)
BR112020008836A2 (pt) Moduladores da via de estresse integrada
WO2017202816A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
RS61401B1 (sr) 2-heteroaril-3-okso-2,3-dihidropiridazin-4-karboksamidi za lečenje raka
JP2019520344A5 (cg-RX-API-DMAC7.html)
JP2017502940A5 (cg-RX-API-DMAC7.html)
JP2014528464A5 (cg-RX-API-DMAC7.html)
JP2010510237A5 (cg-RX-API-DMAC7.html)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения